Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 51 | 2019 | 207 | 7.910 |
Why?
|
Skin | 25 | 2018 | 205 | 3.690 |
Why?
|
Exanthema | 4 | 2018 | 21 | 1.920 |
Why?
|
Immunohistochemistry | 27 | 2019 | 520 | 1.680 |
Why?
|
Carcinoma, Squamous Cell | 8 | 2019 | 149 | 1.490 |
Why?
|
Skin Diseases | 11 | 2017 | 138 | 1.470 |
Why?
|
Humans | 130 | 2019 | 29553 | 1.410 |
Why?
|
Skin Diseases, Vascular | 6 | 2019 | 9 | 1.400 |
Why?
|
Dermatology | 11 | 2017 | 154 | 1.240 |
Why?
|
Xanthomatosis | 2 | 2017 | 3 | 1.210 |
Why?
|
Diagnosis, Differential | 29 | 2019 | 493 | 1.180 |
Why?
|
Hemangioendothelioma | 6 | 2015 | 11 | 1.100 |
Why?
|
Pathology | 7 | 2013 | 20 | 1.060 |
Why?
|
Middle Aged | 58 | 2019 | 10936 | 1.010 |
Why?
|
Female | 73 | 2019 | 18379 | 1.000 |
Why?
|
Mycosis Fungoides | 6 | 2017 | 13 | 0.990 |
Why?
|
Soft Tissue Neoplasms | 5 | 2018 | 35 | 0.970 |
Why?
|
Tattooing | 3 | 2017 | 7 | 0.940 |
Why?
|
Melanoma | 10 | 2014 | 148 | 0.930 |
Why?
|
Pellagra | 2 | 2016 | 3 | 0.930 |
Why?
|
Lichen Sclerosus et Atrophicus | 2 | 2017 | 7 | 0.900 |
Why?
|
Erythema | 5 | 2016 | 27 | 0.880 |
Why?
|
Adult | 43 | 2018 | 8528 | 0.860 |
Why?
|
Biopsy, Needle | 9 | 2019 | 90 | 0.860 |
Why?
|
Male | 58 | 2019 | 18012 | 0.840 |
Why?
|
Aged | 41 | 2019 | 9590 | 0.800 |
Why?
|
Telangiectasis | 3 | 2019 | 3 | 0.790 |
Why?
|
Carcinoma, Merkel Cell | 2 | 2019 | 10 | 0.770 |
Why?
|
Sweet Syndrome | 2 | 2019 | 7 | 0.740 |
Why?
|
Immunocompromised Host | 3 | 2019 | 43 | 0.740 |
Why?
|
Biopsy | 12 | 2017 | 243 | 0.740 |
Why?
|
Collagen Type I | 1 | 2019 | 39 | 0.700 |
Why?
|
Cellulitis | 1 | 2019 | 11 | 0.700 |
Why?
|
Streptococcal Infections | 1 | 2019 | 20 | 0.690 |
Why?
|
Deficiency Diseases | 2 | 2010 | 4 | 0.680 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2019 | 20 | 0.680 |
Why?
|
Zinc | 2 | 2010 | 32 | 0.660 |
Why?
|
Leukemic Infiltration | 1 | 2018 | 2 | 0.660 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 9 | 0.650 |
Why?
|
Ossification, Heterotopic | 2 | 2009 | 14 | 0.650 |
Why?
|
Anti-Bacterial Agents | 2 | 2019 | 286 | 0.640 |
Why?
|
Pagetoid Reticulosis | 1 | 2018 | 2 | 0.630 |
Why?
|
Coloring Agents | 2 | 2017 | 30 | 0.610 |
Why?
|
Fibroma | 3 | 2014 | 11 | 0.610 |
Why?
|
Certification | 3 | 2009 | 25 | 0.610 |
Why?
|
Mast Cells | 2 | 2017 | 17 | 0.610 |
Why?
|
Panniculitis, Lupus Erythematosus | 3 | 2014 | 5 | 0.610 |
Why?
|
Urticaria Pigmentosa | 1 | 2017 | 1 | 0.600 |
Why?
|
Pathology, Clinical | 3 | 2018 | 14 | 0.580 |
Why?
|
Hand Dermatoses | 2 | 2016 | 10 | 0.580 |
Why?
|
Hemangiosarcoma | 4 | 2010 | 8 | 0.540 |
Why?
|
Thigh | 2 | 2019 | 39 | 0.540 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2015 | 4 | 0.530 |
Why?
|
Scalp | 2 | 2007 | 33 | 0.510 |
Why?
|
Dermatitis | 4 | 2017 | 20 | 0.490 |
Why?
|
Blood Vessels | 2 | 2009 | 47 | 0.480 |
Why?
|
Histiocytoma, Benign Fibrous | 4 | 2009 | 4 | 0.480 |
Why?
|
Neoplasm Invasiveness | 5 | 2014 | 189 | 0.470 |
Why?
|
Neoplasms, Adnexal and Skin Appendage | 1 | 2013 | 2 | 0.460 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2013 | 3 | 0.460 |
Why?
|
Head and Neck Neoplasms | 2 | 2007 | 123 | 0.460 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2015 | 337 | 0.430 |
Why?
|
Parakeratosis | 2 | 2003 | 2 | 0.430 |
Why?
|
Axilla | 2 | 2003 | 15 | 0.420 |
Why?
|
Hemangioma | 3 | 2009 | 18 | 0.420 |
Why?
|
Treatment Outcome | 8 | 2019 | 3128 | 0.420 |
Why?
|
Fingers | 2 | 2008 | 57 | 0.420 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2002 | 41 | 0.410 |
Why?
|
Keratinocytes | 2 | 2010 | 26 | 0.400 |
Why?
|
Polycythemia Vera | 1 | 2010 | 2 | 0.380 |
Why?
|
Paracoccidioidomycosis | 2 | 2009 | 2 | 0.380 |
Why?
|
Niacin | 1 | 2010 | 7 | 0.380 |
Why?
|
Acantholysis | 1 | 2010 | 1 | 0.380 |
Why?
|
Ichthyosis | 1 | 2010 | 1 | 0.380 |
Why?
|
Epidermis | 5 | 2011 | 25 | 0.370 |
Why?
|
Giant Cells | 2 | 2009 | 4 | 0.360 |
Why?
|
Tongue Neoplasms | 3 | 2003 | 5 | 0.360 |
Why?
|
Epithelioid Cells | 1 | 2009 | 1 | 0.350 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 1 | 2009 | 1 | 0.350 |
Why?
|
Desmin | 1 | 2009 | 12 | 0.350 |
Why?
|
Mycoses | 2 | 2009 | 13 | 0.350 |
Why?
|
Child | 8 | 2017 | 2233 | 0.340 |
Why?
|
Sialoglycoproteins | 2 | 2008 | 7 | 0.340 |
Why?
|
Osteoclasts | 1 | 2009 | 22 | 0.340 |
Why?
|
Paracoccidioides | 1 | 2009 | 1 | 0.340 |
Why?
|
Bottle-Nosed Dolphin | 1 | 2009 | 1 | 0.340 |
Why?
|
Dermatomyositis | 1 | 2009 | 19 | 0.330 |
Why?
|
Neoplasms, Vascular Tissue | 3 | 2013 | 7 | 0.320 |
Why?
|
Lymphoma, B-Cell | 2 | 2002 | 12 | 0.320 |
Why?
|
Endothelium, Lymphatic | 1 | 2008 | 1 | 0.320 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 1 | 2008 | 1 | 0.320 |
Why?
|
Keratoacanthoma | 1 | 2008 | 1 | 0.310 |
Why?
|
Antigens, CD | 4 | 2009 | 100 | 0.310 |
Why?
|
Mouth Mucosa | 1 | 2008 | 29 | 0.310 |
Why?
|
Transglutaminases | 1 | 2007 | 1 | 0.310 |
Why?
|
Epidermal Cyst | 1 | 2007 | 4 | 0.310 |
Why?
|
Acrodermatitis | 1 | 2007 | 1 | 0.300 |
Why?
|
Arm | 2 | 2017 | 31 | 0.300 |
Why?
|
Renal Insufficiency | 1 | 2007 | 53 | 0.300 |
Why?
|
Carcinoma | 3 | 2013 | 89 | 0.290 |
Why?
|
Aged, 80 and over | 14 | 2014 | 3764 | 0.290 |
Why?
|
Upper Extremity | 3 | 2017 | 53 | 0.280 |
Why?
|
Hypopigmentation | 3 | 2017 | 7 | 0.270 |
Why?
|
Hamartoma | 2 | 1997 | 11 | 0.270 |
Why?
|
Neurilemmoma | 2 | 2005 | 14 | 0.270 |
Why?
|
Opportunistic Infections | 2 | 2002 | 9 | 0.270 |
Why?
|
Adolescent | 12 | 2013 | 3284 | 0.270 |
Why?
|
Lower Extremity | 2 | 2017 | 97 | 0.270 |
Why?
|
Granuloma | 2 | 2002 | 13 | 0.270 |
Why?
|
Specialty Boards | 1 | 2005 | 9 | 0.260 |
Why?
|
Eyelid Neoplasms | 2 | 2018 | 3 | 0.260 |
Why?
|
Risk Assessment | 4 | 2019 | 1329 | 0.260 |
Why?
|
Carcinoma, Basal Cell | 3 | 2014 | 27 | 0.250 |
Why?
|
Drug Therapy, Combination | 3 | 2019 | 275 | 0.250 |
Why?
|
Mass Screening | 1 | 2007 | 227 | 0.250 |
Why?
|
Education, Medical, Graduate | 3 | 2012 | 116 | 0.250 |
Why?
|
Dermatomycoses | 2 | 2002 | 6 | 0.250 |
Why?
|
Eye Neoplasms | 1 | 2004 | 4 | 0.240 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2004 | 11 | 0.240 |
Why?
|
Facial Neoplasms | 2 | 2001 | 10 | 0.240 |
Why?
|
Lupus Erythematosus, Discoid | 2 | 2004 | 8 | 0.230 |
Why?
|
Remission, Spontaneous | 4 | 2015 | 14 | 0.230 |
Why?
|
Glomus Tumor | 3 | 2017 | 6 | 0.230 |
Why?
|
Ganglioneuroma | 1 | 2003 | 2 | 0.230 |
Why?
|
Sarcoma, Alveolar Soft Part | 1 | 2003 | 1 | 0.230 |
Why?
|
Flow Cytometry | 3 | 2005 | 173 | 0.220 |
Why?
|
Multiple Myeloma | 1 | 2003 | 15 | 0.220 |
Why?
|
Prognosis | 6 | 2015 | 1372 | 0.220 |
Why?
|
Fusarium | 1 | 2002 | 1 | 0.220 |
Why?
|
Fibrosarcoma | 1 | 2002 | 3 | 0.220 |
Why?
|
Keratosis, Actinic | 2 | 2015 | 18 | 0.220 |
Why?
|
Lymph Nodes | 2 | 2019 | 94 | 0.220 |
Why?
|
Eosinophils | 2 | 2014 | 48 | 0.210 |
Why?
|
Rare Diseases | 2 | 2019 | 20 | 0.210 |
Why?
|
Tetrahydronaphthalenes | 1 | 2002 | 7 | 0.210 |
Why?
|
Gingival Neoplasms | 1 | 2002 | 1 | 0.210 |
Why?
|
DNA, Neoplasm | 2 | 1993 | 58 | 0.210 |
Why?
|
Arthritis, Rheumatoid | 1 | 2002 | 33 | 0.210 |
Why?
|
Periodontitis | 1 | 2002 | 9 | 0.210 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2002 | 15 | 0.210 |
Why?
|
Neoplasm Proteins | 6 | 2009 | 141 | 0.210 |
Why?
|
Precancerous Conditions | 2 | 2013 | 24 | 0.200 |
Why?
|
Carcinoma, Skin Appendage | 1 | 2001 | 1 | 0.200 |
Why?
|
Darier Disease | 1 | 2001 | 2 | 0.200 |
Why?
|
S100 Proteins | 5 | 2005 | 18 | 0.200 |
Why?
|
Antigens, Neoplasm | 4 | 2009 | 44 | 0.190 |
Why?
|
Toes | 2 | 2017 | 16 | 0.190 |
Why?
|
Hyperpigmentation | 2 | 2013 | 17 | 0.190 |
Why?
|
Endothelium, Vascular | 4 | 2009 | 145 | 0.190 |
Why?
|
Image Processing, Computer-Assisted | 2 | 1993 | 242 | 0.190 |
Why?
|
Immunosuppressive Agents | 2 | 2006 | 168 | 0.190 |
Why?
|
Neoplasms, Basal Cell | 1 | 2000 | 2 | 0.180 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2000 | 13 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 37 | 0.180 |
Why?
|
Dermis | 5 | 2009 | 12 | 0.180 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 156 | 0.180 |
Why?
|
Predictive Value of Tests | 5 | 2013 | 796 | 0.180 |
Why?
|
Ki-67 Antigen | 1 | 2000 | 29 | 0.180 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2000 | 78 | 0.180 |
Why?
|
Streptococcus | 1 | 2019 | 7 | 0.180 |
Why?
|
Pemphigoid, Bullous | 1 | 2019 | 6 | 0.180 |
Why?
|
Knee | 1 | 2019 | 31 | 0.170 |
Why?
|
Elbow | 1 | 2019 | 25 | 0.170 |
Why?
|
Retrospective Studies | 7 | 2011 | 3144 | 0.170 |
Why?
|
Xanthogranuloma, Juvenile | 1 | 1999 | 2 | 0.170 |
Why?
|
Fever | 1 | 2019 | 56 | 0.170 |
Why?
|
Eccrine Glands | 2 | 1997 | 2 | 0.170 |
Why?
|
Arteriovenous Fistula | 1 | 1999 | 14 | 0.170 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1999 | 20 | 0.170 |
Why?
|
Actinomycosis | 1 | 1998 | 2 | 0.160 |
Why?
|
Oral Ulcer | 1 | 1998 | 5 | 0.160 |
Why?
|
Antigens, CD7 | 1 | 2018 | 4 | 0.160 |
Why?
|
Chondroma | 1 | 2018 | 2 | 0.160 |
Why?
|
Palate | 1 | 1998 | 5 | 0.160 |
Why?
|
Bone Marrow Examination | 1 | 2018 | 8 | 0.160 |
Why?
|
Nevus | 2 | 2004 | 15 | 0.160 |
Why?
|
Vascular Neoplasms | 3 | 2009 | 14 | 0.160 |
Why?
|
Vulvar Neoplasms | 2 | 2013 | 6 | 0.160 |
Why?
|
Child, Preschool | 6 | 2013 | 1172 | 0.160 |
Why?
|
Foot | 1 | 2018 | 40 | 0.150 |
Why?
|
Prednisone | 3 | 2008 | 43 | 0.150 |
Why?
|
Severity of Illness Index | 2 | 2019 | 864 | 0.150 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2018 | 113 | 0.150 |
Why?
|
Dermatitis, Allergic Contact | 1 | 2017 | 11 | 0.150 |
Why?
|
Lacrimal Apparatus Diseases | 1 | 2017 | 2 | 0.150 |
Why?
|
Eyelids | 1 | 2017 | 9 | 0.150 |
Why?
|
Nail Diseases | 1 | 2017 | 3 | 0.150 |
Why?
|
Conjunctiva | 1 | 2017 | 5 | 0.150 |
Why?
|
Lacrimal Apparatus | 1 | 2017 | 6 | 0.150 |
Why?
|
Angiomyoma | 1 | 2017 | 3 | 0.150 |
Why?
|
Conjunctival Diseases | 1 | 2017 | 4 | 0.150 |
Why?
|
Administration, Oral | 2 | 2008 | 172 | 0.150 |
Why?
|
Hyperplasia | 5 | 2013 | 38 | 0.140 |
Why?
|
Skin Pigmentation | 1 | 2017 | 23 | 0.140 |
Why?
|
Cladribine | 1 | 1996 | 1 | 0.140 |
Why?
|
Myxedema | 1 | 1996 | 3 | 0.140 |
Why?
|
Cell Differentiation | 3 | 2013 | 438 | 0.140 |
Why?
|
Scleroderma, Systemic | 1 | 1996 | 7 | 0.140 |
Why?
|
Immunoenzyme Techniques | 5 | 2004 | 47 | 0.140 |
Why?
|
Telemedicine | 1 | 2017 | 79 | 0.140 |
Why?
|
Terminology as Topic | 2 | 1993 | 63 | 0.140 |
Why?
|
Sparganosis | 1 | 2016 | 1 | 0.140 |
Why?
|
Sparganum | 1 | 2016 | 1 | 0.140 |
Why?
|
Zoonoses | 1 | 2016 | 3 | 0.140 |
Why?
|
Skin Diseases, Infectious | 1 | 2016 | 3 | 0.140 |
Why?
|
Antinematodal Agents | 1 | 2015 | 1 | 0.140 |
Why?
|
Skin Diseases, Parasitic | 1 | 2015 | 1 | 0.140 |
Why?
|
Nematoda | 1 | 2015 | 2 | 0.140 |
Why?
|
Nematode Infections | 1 | 2015 | 2 | 0.140 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 440 | 0.130 |
Why?
|
Sarcoma, Kaposi | 3 | 2002 | 7 | 0.130 |
Why?
|
Lymphocytes | 3 | 2010 | 55 | 0.130 |
Why?
|
Hidradenitis | 1 | 1995 | 1 | 0.130 |
Why?
|
Liver Diseases, Alcoholic | 1 | 1995 | 5 | 0.130 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 1995 | 10 | 0.130 |
Why?
|
Herpes Simplex | 1 | 1995 | 12 | 0.130 |
Why?
|
Herpes Zoster | 1 | 1995 | 9 | 0.130 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 401 | 0.130 |
Why?
|
Administration, Topical | 2 | 2007 | 130 | 0.130 |
Why?
|
Kidney Transplantation | 1 | 2019 | 353 | 0.130 |
Why?
|
Hemochromatosis | 1 | 1995 | 70 | 0.120 |
Why?
|
Infant | 5 | 2013 | 976 | 0.120 |
Why?
|
Liver Diseases | 1 | 1995 | 62 | 0.120 |
Why?
|
Breast Neoplasms | 2 | 2002 | 680 | 0.120 |
Why?
|
Rhinophyma | 1 | 1994 | 2 | 0.120 |
Why?
|
Mohs Surgery | 2 | 2007 | 16 | 0.120 |
Why?
|
Europe | 3 | 2016 | 78 | 0.120 |
Why?
|
Education, Medical, Continuing | 2 | 2012 | 45 | 0.120 |
Why?
|
Chordoma | 1 | 1994 | 7 | 0.120 |
Why?
|
Pruritus | 1 | 2014 | 58 | 0.120 |
Why?
|
African Americans | 1 | 2001 | 1375 | 0.120 |
Why?
|
Infrared Rays | 1 | 2013 | 18 | 0.110 |
Why?
|
Leishmaniasis, Mucocutaneous | 1 | 1993 | 1 | 0.110 |
Why?
|
Wrestling | 1 | 1993 | 2 | 0.110 |
Why?
|
Combined Modality Therapy | 3 | 2015 | 525 | 0.110 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2013 | 13 | 0.110 |
Why?
|
Tinea | 1 | 1993 | 4 | 0.110 |
Why?
|
Penile Neoplasms | 2 | 2004 | 6 | 0.110 |
Why?
|
Dysplastic Nevus Syndrome | 1 | 1993 | 3 | 0.110 |
Why?
|
Calcinosis | 1 | 2014 | 143 | 0.110 |
Why?
|
Lymphoma | 2 | 1993 | 36 | 0.110 |
Why?
|
Contrast Media | 2 | 2007 | 124 | 0.110 |
Why?
|
Disease Outbreaks | 1 | 1993 | 35 | 0.110 |
Why?
|
Neoplasms, Second Primary | 1 | 1992 | 16 | 0.110 |
Why?
|
PUVA Therapy | 2 | 2009 | 22 | 0.110 |
Why?
|
Back | 2 | 2010 | 3 | 0.110 |
Why?
|
Myoepithelioma | 2 | 2003 | 2 | 0.110 |
Why?
|
Glucocorticoids | 3 | 2009 | 149 | 0.110 |
Why?
|
Pregnancy | 1 | 2015 | 825 | 0.110 |
Why?
|
Neoplasm Staging | 3 | 2010 | 441 | 0.100 |
Why?
|
Pain | 1 | 2014 | 285 | 0.100 |
Why?
|
T-Lymphocytes | 1 | 1992 | 116 | 0.100 |
Why?
|
Phenotype | 1 | 2013 | 633 | 0.100 |
Why?
|
Eczema | 1 | 2011 | 12 | 0.100 |
Why?
|
Histiocytes | 2 | 2009 | 3 | 0.100 |
Why?
|
Nerve Fibers | 1 | 2011 | 31 | 0.100 |
Why?
|
Inflammation | 1 | 2014 | 511 | 0.100 |
Why?
|
Groin | 1 | 2010 | 5 | 0.100 |
Why?
|
Rhabdomyoma | 1 | 1990 | 3 | 0.090 |
Why?
|
Lymphangioma | 2 | 2002 | 6 | 0.090 |
Why?
|
Evidence-Based Medicine | 2 | 2015 | 209 | 0.090 |
Why?
|
Leg | 1 | 2010 | 57 | 0.090 |
Why?
|
DNA | 1 | 1992 | 209 | 0.090 |
Why?
|
Hutchinson's Melanotic Freckle | 1 | 2010 | 2 | 0.090 |
Why?
|
Governing Board | 1 | 2009 | 1 | 0.090 |
Why?
|
Paget's Disease, Mammary | 2 | 2002 | 3 | 0.090 |
Why?
|
Fibrosis | 2 | 2007 | 104 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 1 | 2013 | 840 | 0.090 |
Why?
|
History, 21st Century | 1 | 2009 | 49 | 0.090 |
Why?
|
History, 20th Century | 1 | 2009 | 69 | 0.090 |
Why?
|
Radiography | 2 | 2008 | 355 | 0.090 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 1 | 2009 | 6 | 0.090 |
Why?
|
Actins | 1 | 2009 | 52 | 0.090 |
Why?
|
Histiocytosis | 1 | 2009 | 1 | 0.090 |
Why?
|
Lymphatic Vessels | 1 | 2009 | 5 | 0.090 |
Why?
|
Clobetasol | 1 | 2009 | 25 | 0.090 |
Why?
|
Brazil | 1 | 2009 | 13 | 0.080 |
Why?
|
Purpura | 2 | 1999 | 3 | 0.080 |
Why?
|
Mastocytosis, Cutaneous | 1 | 2008 | 3 | 0.080 |
Why?
|
Radiopharmaceuticals | 1 | 2009 | 89 | 0.080 |
Why?
|
Renal Dialysis | 2 | 2003 | 265 | 0.080 |
Why?
|
Immunophenotyping | 3 | 1993 | 50 | 0.080 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2008 | 1 | 0.080 |
Why?
|
Granuloma Annulare | 1 | 2008 | 2 | 0.080 |
Why?
|
Survival Analysis | 2 | 2007 | 440 | 0.080 |
Why?
|
Lymphangiectasis | 2 | 1999 | 3 | 0.080 |
Why?
|
Lip | 1 | 2008 | 8 | 0.080 |
Why?
|
Melanocytes | 3 | 2001 | 8 | 0.080 |
Why?
|
Neurothekeoma | 1 | 2008 | 2 | 0.080 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2008 | 5 | 0.080 |
Why?
|
Endothelial Cells | 1 | 2009 | 180 | 0.080 |
Why?
|
Elastic Tissue | 1 | 2007 | 2 | 0.080 |
Why?
|
Bone Diseases | 1 | 2008 | 16 | 0.080 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2009 | 145 | 0.080 |
Why?
|
Factor XIIIa | 1 | 2007 | 1 | 0.080 |
Why?
|
Gadolinium | 1 | 2007 | 19 | 0.080 |
Why?
|
Atrophy | 1 | 2007 | 52 | 0.080 |
Why?
|
Methotrexate | 1 | 2008 | 60 | 0.080 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 22 | 0.080 |
Why?
|
Syndrome | 1 | 2007 | 66 | 0.080 |
Why?
|
Injections, Intravenous | 1 | 2007 | 73 | 0.070 |
Why?
|
Extremities | 1 | 2007 | 48 | 0.070 |
Why?
|
Fibroblasts | 1 | 2007 | 105 | 0.070 |
Why?
|
Career Choice | 1 | 2007 | 40 | 0.070 |
Why?
|
Early Diagnosis | 1 | 2007 | 62 | 0.070 |
Why?
|
Fellowships and Scholarships | 1 | 2007 | 50 | 0.070 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2007 | 69 | 0.070 |
Why?
|
Family Practice | 1 | 2007 | 49 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2007 | 163 | 0.070 |
Why?
|
Skin Ulcer | 1 | 2006 | 10 | 0.070 |
Why?
|
Germany | 1 | 2006 | 8 | 0.070 |
Why?
|
Keratins | 3 | 1998 | 38 | 0.070 |
Why?
|
Antibodies, Monoclonal | 1 | 2008 | 198 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2007 | 150 | 0.070 |
Why?
|
Polychondritis, Relapsing | 1 | 2006 | 2 | 0.070 |
Why?
|
Cytomegalovirus Infections | 1 | 2006 | 25 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 3 | 2017 | 1225 | 0.070 |
Why?
|
Mycophenolic Acid | 1 | 2006 | 28 | 0.070 |
Why?
|
Dilatation, Pathologic | 2 | 2013 | 19 | 0.070 |
Why?
|
Animals | 3 | 2016 | 7339 | 0.070 |
Why?
|
Microtubule-Associated Proteins | 1 | 2005 | 33 | 0.060 |
Why?
|
Nevus, Blue | 2 | 2002 | 2 | 0.060 |
Why?
|
Case-Control Studies | 1 | 2007 | 861 | 0.060 |
Why?
|
Neuroblastoma | 1 | 2005 | 32 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2006 | 91 | 0.060 |
Why?
|
Necrosis | 2 | 1995 | 53 | 0.060 |
Why?
|
Follow-Up Studies | 2 | 2008 | 2124 | 0.060 |
Why?
|
Fatal Outcome | 2 | 2008 | 79 | 0.060 |
Why?
|
Recombinant Fusion Proteins | 1 | 2004 | 97 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2007 | 471 | 0.060 |
Why?
|
Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2004 | 2 | 0.060 |
Why?
|
Immunoglobulin G | 1 | 2004 | 105 | 0.060 |
Why?
|
Neurofilament Proteins | 1 | 2003 | 11 | 0.060 |
Why?
|
Mixed Tumor, Malignant | 1 | 2003 | 1 | 0.060 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2003 | 37 | 0.060 |
Why?
|
Genes, Retinoblastoma | 1 | 2003 | 4 | 0.060 |
Why?
|
Triamcinolone | 1 | 2003 | 11 | 0.060 |
Why?
|
Immunoglobulins | 1 | 2003 | 12 | 0.060 |
Why?
|
Plasma Cells | 1 | 2003 | 8 | 0.060 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2003 | 38 | 0.060 |
Why?
|
Cell Nucleus | 2 | 1995 | 109 | 0.060 |
Why?
|
Gene Deletion | 1 | 2003 | 65 | 0.060 |
Why?
|
Actinomycetales | 1 | 2002 | 1 | 0.060 |
Why?
|
Lip Neoplasms | 1 | 2002 | 1 | 0.060 |
Why?
|
Syphilis, Cutaneous | 1 | 2002 | 1 | 0.060 |
Why?
|
Skin Diseases, Papulosquamous | 1 | 2002 | 1 | 0.060 |
Why?
|
Leukemia, Lymphoid | 1 | 2002 | 2 | 0.060 |
Why?
|
Corynebacterium Infections | 1 | 2002 | 2 | 0.060 |
Why?
|
Nevus, Epithelioid and Spindle Cell | 1 | 2002 | 3 | 0.050 |
Why?
|
Angiomatosis | 1 | 2002 | 3 | 0.050 |
Why?
|
Nevus, Pigmented | 1 | 2002 | 5 | 0.050 |
Why?
|
Salivary Gland Neoplasms | 1 | 2002 | 12 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2005 | 576 | 0.050 |
Why?
|
Adenoma | 1 | 2002 | 35 | 0.050 |
Why?
|
Pigmentation Disorders | 1 | 2002 | 8 | 0.050 |
Why?
|
Sarcoidosis | 2 | 2002 | 27 | 0.050 |
Why?
|
Neutrophils | 1 | 2002 | 102 | 0.050 |
Why?
|
Internship and Residency | 1 | 2005 | 283 | 0.050 |
Why?
|
Dermatitis, Atopic | 1 | 2002 | 86 | 0.050 |
Why?
|
Disease Progression | 2 | 2015 | 574 | 0.050 |
Why?
|
Basal Cell Nevus Syndrome | 1 | 1999 | 1 | 0.040 |
Why?
|
Psoriasis | 1 | 2004 | 334 | 0.040 |
Why?
|
Leukemia, Hairy Cell | 1 | 1999 | 1 | 0.040 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 1999 | 1 | 0.040 |
Why?
|
Panniculitis | 1 | 1999 | 3 | 0.040 |
Why?
|
Collagen Diseases | 1 | 1999 | 5 | 0.040 |
Why?
|
Skin Diseases, Viral | 1 | 1999 | 4 | 0.040 |
Why?
|
Skin Diseases, Genetic | 1 | 1999 | 3 | 0.040 |
Why?
|
Graft vs Host Disease | 1 | 1999 | 18 | 0.040 |
Why?
|
Vasculitis | 1 | 1999 | 23 | 0.040 |
Why?
|
Bone Marrow Transplantation | 1 | 1999 | 65 | 0.040 |
Why?
|
Diatrizoate Meglumine | 1 | 1998 | 1 | 0.040 |
Why?
|
Hyperkeratosis, Epidermolytic | 1 | 1998 | 1 | 0.040 |
Why?
|
Drug Eruptions | 1 | 1998 | 8 | 0.040 |
Why?
|
Registries | 2 | 2010 | 280 | 0.040 |
Why?
|
Angiolipoma | 1 | 1998 | 1 | 0.040 |
Why?
|
Carcinoma, Adenosquamous | 1 | 1998 | 3 | 0.040 |
Why?
|
Angiofibroma | 1 | 1998 | 2 | 0.040 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 1998 | 3 | 0.040 |
Why?
|
Angiomyolipoma | 1 | 1998 | 6 | 0.040 |
Why?
|
Myxoma | 1 | 1998 | 4 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 1 | 2003 | 874 | 0.040 |
Why?
|
Software | 1 | 2018 | 110 | 0.040 |
Why?
|
Angiomatosis, Bacillary | 1 | 1997 | 1 | 0.040 |
Why?
|
Hemangioma, Cavernous | 1 | 1997 | 3 | 0.040 |
Why?
|
Angiolymphoid Hyperplasia with Eosinophilia | 1 | 1997 | 3 | 0.040 |
Why?
|
Granuloma, Pyogenic | 1 | 1997 | 4 | 0.040 |
Why?
|
Hemangioma, Capillary | 1 | 1997 | 3 | 0.040 |
Why?
|
Hemangiopericytoma | 1 | 1997 | 6 | 0.040 |
Why?
|
Angiokeratoma | 1 | 1997 | 2 | 0.040 |
Why?
|
Venules | 1 | 1997 | 5 | 0.040 |
Why?
|
Lymphatic System | 1 | 1997 | 2 | 0.040 |
Why?
|
Neoplasm Regression, Spontaneous | 1 | 1997 | 6 | 0.040 |
Why?
|
Veins | 1 | 1997 | 29 | 0.040 |
Why?
|
Capillaries | 1 | 1997 | 23 | 0.040 |
Why?
|
Acute Disease | 1 | 1998 | 239 | 0.040 |
Why?
|
Cell Lineage | 1 | 1997 | 67 | 0.040 |
Why?
|
Aneurysm | 1 | 1997 | 21 | 0.040 |
Why?
|
Oculomotor Muscles | 1 | 1997 | 5 | 0.040 |
Why?
|
Eye Diseases | 1 | 1997 | 5 | 0.040 |
Why?
|
Observer Variation | 1 | 2017 | 96 | 0.040 |
Why?
|
Melanins | 1 | 1996 | 6 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2017 | 270 | 0.040 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2009 | 69 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 1996 | 85 | 0.030 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 1996 | 28 | 0.030 |
Why?
|
Seawater | 1 | 2016 | 2 | 0.030 |
Why?
|
Praziquantel | 1 | 2016 | 2 | 0.030 |
Why?
|
Blotting, Southern | 2 | 1993 | 22 | 0.030 |
Why?
|
Genes, Immunoglobulin | 2 | 1993 | 5 | 0.030 |
Why?
|
Gene Rearrangement | 2 | 1993 | 10 | 0.030 |
Why?
|
Italy | 1 | 2016 | 15 | 0.030 |
Why?
|
Anthelmintics | 1 | 2016 | 3 | 0.030 |
Why?
|
Helminthiasis | 1 | 2015 | 1 | 0.030 |
Why?
|
Helminths | 1 | 2015 | 1 | 0.030 |
Why?
|
Tropical Climate | 1 | 2015 | 1 | 0.030 |
Why?
|
Endemic Diseases | 1 | 2015 | 4 | 0.030 |
Why?
|
Ophthalmologic Surgical Procedures | 2 | 2010 | 3 | 0.030 |
Why?
|
Glucagonoma | 1 | 1995 | 1 | 0.030 |
Why?
|
Sebaceous Glands | 1 | 1995 | 2 | 0.030 |
Why?
|
Inclusion Bodies, Viral | 1 | 1995 | 4 | 0.030 |
Why?
|
Young Adult | 2 | 2013 | 2431 | 0.030 |
Why?
|
Tongue Diseases | 1 | 1995 | 4 | 0.030 |
Why?
|
Hair Follicle | 1 | 1995 | 9 | 0.030 |
Why?
|
Chromatin | 1 | 1995 | 20 | 0.030 |
Why?
|
Edema | 1 | 1995 | 30 | 0.030 |
Why?
|
Keratosis | 1 | 1995 | 19 | 0.030 |
Why?
|
Cytoplasm | 1 | 1995 | 32 | 0.030 |
Why?
|
Serum Albumin | 1 | 1995 | 53 | 0.030 |
Why?
|
Kidney Failure, Chronic | 1 | 1999 | 522 | 0.030 |
Why?
|
Facial Dermatoses | 1 | 1994 | 19 | 0.030 |
Why?
|
Dental Instruments | 1 | 1993 | 1 | 0.030 |
Why?
|
Nails | 1 | 1993 | 6 | 0.030 |
Why?
|
Curettage | 1 | 1993 | 9 | 0.030 |
Why?
|
Onychomycosis | 1 | 1993 | 9 | 0.030 |
Why?
|
Leishmaniasis, Diffuse Cutaneous | 1 | 1993 | 1 | 0.030 |
Why?
|
Bolivia | 1 | 1993 | 2 | 0.030 |
Why?
|
Leishmaniasis, Cutaneous | 1 | 1993 | 2 | 0.030 |
Why?
|
Specimen Handling | 1 | 1993 | 31 | 0.030 |
Why?
|
Diploidy | 1 | 1993 | 2 | 0.030 |
Why?
|
Vascular Malformations | 1 | 2013 | 8 | 0.030 |
Why?
|
Pain Measurement | 1 | 2014 | 365 | 0.030 |
Why?
|
Microscopy | 1 | 1993 | 27 | 0.030 |
Why?
|
Antifungal Agents | 1 | 1993 | 34 | 0.030 |
Why?
|
Stromal Cells | 1 | 2013 | 70 | 0.030 |
Why?
|
Rhabdomyosarcoma | 1 | 1992 | 6 | 0.030 |
Why?
|
Microscopy, Electron | 1 | 1992 | 29 | 0.030 |
Why?
|
Credentialing | 1 | 2012 | 8 | 0.030 |
Why?
|
Wilms Tumor | 1 | 1992 | 14 | 0.030 |
Why?
|
Incidence | 1 | 2015 | 1127 | 0.030 |
Why?
|
Task Performance and Analysis | 1 | 2012 | 51 | 0.030 |
Why?
|
Ploidies | 1 | 1992 | 7 | 0.030 |
Why?
|
Aneuploidy | 1 | 1992 | 8 | 0.030 |
Why?
|
Prevalence | 1 | 2014 | 910 | 0.030 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2011 | 9 | 0.030 |
Why?
|
Program Evaluation | 1 | 2012 | 176 | 0.030 |
Why?
|
Educational Measurement | 1 | 2012 | 113 | 0.020 |
Why?
|
Societies, Medical | 1 | 2012 | 150 | 0.020 |
Why?
|
Genotype | 1 | 1993 | 735 | 0.020 |
Why?
|
Austria | 1 | 2010 | 3 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2010 | 141 | 0.020 |
Why?
|
Dermoscopy | 1 | 2010 | 8 | 0.020 |
Why?
|
Radiotherapy | 1 | 2010 | 76 | 0.020 |
Why?
|
Rosaniline Dyes | 1 | 2009 | 19 | 0.020 |
Why?
|
Prospective Studies | 1 | 2014 | 2046 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 2009 | 23 | 0.020 |
Why?
|
Phosphoglucomutase | 1 | 2009 | 5 | 0.020 |
Why?
|
Eyelid Diseases | 1 | 2009 | 4 | 0.020 |
Why?
|
Intraoperative Care | 1 | 2009 | 48 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 533 | 0.020 |
Why?
|
Silver Sulfadiazine | 1 | 2008 | 4 | 0.020 |
Why?
|
Fluocinonide | 1 | 2008 | 11 | 0.020 |
Why?
|
Anti-Infective Agents, Local | 1 | 2008 | 13 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2008 | 24 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2009 | 107 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2009 | 294 | 0.020 |
Why?
|
Azacitidine | 1 | 2008 | 28 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2008 | 48 | 0.020 |
Why?
|
Time Factors | 1 | 2013 | 2014 | 0.020 |
Why?
|
Cohort Studies | 1 | 2010 | 1701 | 0.020 |
Why?
|
Perineum | 1 | 2006 | 14 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2008 | 605 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2010 | 548 | 0.020 |
Why?
|
Risk Factors | 1 | 2013 | 3600 | 0.020 |
Why?
|
Mitosis | 1 | 2005 | 23 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2004 | 50 | 0.020 |
Why?
|
Blotting, Western | 1 | 2005 | 286 | 0.020 |
Why?
|
Periodicals as Topic | 1 | 2005 | 95 | 0.010 |
Why?
|
Apoptosis | 1 | 2005 | 352 | 0.010 |
Why?
|
Leprosy | 1 | 2002 | 1 | 0.010 |
Why?
|
Neurofibroma | 1 | 2002 | 1 | 0.010 |
Why?
|
Antibodies, Anticardiolipin | 1 | 2002 | 4 | 0.010 |
Why?
|
Leishmaniasis | 1 | 2002 | 3 | 0.010 |
Why?
|
Germinal Center | 1 | 2002 | 5 | 0.010 |
Why?
|
Clone Cells | 1 | 2002 | 36 | 0.010 |
Why?
|
Salivary Glands, Minor | 1 | 2002 | 9 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 692 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2004 | 199 | 0.010 |
Why?
|
HIV-1 | 1 | 2002 | 45 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2003 | 282 | 0.010 |
Why?
|
Breast | 1 | 2002 | 53 | 0.010 |
Why?
|
Neurons | 1 | 2005 | 395 | 0.010 |
Why?
|
Cholesterol | 1 | 2002 | 239 | 0.010 |
Why?
|
Pedigree | 1 | 1999 | 135 | 0.010 |
Why?
|
Breast Neoplasms, Male | 1 | 1999 | 11 | 0.010 |
Why?
|
Carbon Dioxide | 1 | 1999 | 36 | 0.010 |
Why?
|
Hysterosalpingography | 1 | 1998 | 1 | 0.010 |
Why?
|
Laser Therapy | 1 | 1999 | 52 | 0.010 |
Why?
|
Carcinoembryonic Antigen | 1 | 1998 | 7 | 0.010 |
Why?
|
Forearm | 1 | 1998 | 37 | 0.010 |
Why?
|
Cell Adhesion Molecules | 1 | 1998 | 45 | 0.010 |
Why?
|
Depth Perception | 1 | 1997 | 1 | 0.010 |
Why?
|
Eye Movements | 1 | 1997 | 12 | 0.010 |
Why?
|
United States | 1 | 2005 | 3693 | 0.010 |
Why?
|
Visual Acuity | 1 | 1997 | 69 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 1999 | 302 | 0.010 |
Why?
|
Griseofulvin | 1 | 1993 | 1 | 0.010 |
Why?
|
Ketoconazole | 1 | 1993 | 3 | 0.010 |
Why?
|
Itraconazole | 1 | 1993 | 6 | 0.010 |
Why?
|
Fluconazole | 1 | 1993 | 7 | 0.010 |
Why?
|
Molecular Structure | 1 | 1993 | 53 | 0.010 |
Why?
|